Overall, these pre-clinical findings originally suggested that EGFR- and HER2-targeted therapies would disrupt both genomic and non-genomic cross-talk with the ER, and consequently re-sensitize breast cancer cells to tamoxifen and other endocrine therapies [13,14,15]. The gene discussed is ESR1; the disease is breast cancer.